Pds biotech and national cancer institute identify optimal patient group for advancing pds0101-based triple combination program targeting advanced hpv-positive cancers

Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at asco 2022 demonstrating 77% survival at a median of 12 months ongoing program to focus on checkpoint inhibitor refractory patients following data presented at asco 2022 demonstrating 77% survival at a median of 12 months
PDSB Ratings Summary
PDSB Quant Ranking